After the first recurrence, the first injection of H101 led to an increase in CD8+ T cells in peripheral blood, indicating that the oncolytic virus directly lysed tumor cells, releasing a large number of tumor antigens and activating a CD8+ cytotoxic T cell response (17). The gene discussed is CD8A; the disease is neoplasm.